New burn treatment cP12 enters early human testing
Symptom relief
Recruiting now
This study tests a single dose of a new drug called cP12 in 6 adults with thermal burns covering up to 10% of their body. The main goal is to check if the drug is safe and how the body processes it. Researchers will also monitor pain and burn healing for two weeks after treatment…
Phase: PHASE2 • Sponsor: Neomatrix Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC